Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Best Buy Co Inc (BBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Best Buy Co Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Best Buy Co Inc trades at $77.58 (market cap $16.59B). The key difference: Best Buy Co Inc is far larger — about 3.7× ACADIA Pharmaceuticals Inc.'s market cap, and Best Buy Co Inc pays a 4.88% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BBY | |
|---|---|---|
Market Cap | $4.49B | $16.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $84.00 |
52-Week Low | $20.06 | $55.52 |
Enterprise Value | $3.69B | $18.97B |
Dividend Yield | — | 4.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Best Buy (BBY) trades at $78.72, up 0.94% with a bullish technical outlook and positive earnings momentum after beating estimates for three consecutive quarters. The company shows strong profitability with 39.1% ROE and attractive valuation metrics including a 14.44 P/E ratio. Recent leadership transition and strategic focus on higher-margin businesses like marketplace expansion and retail media provide growth catalysts.
The stock offers value with a 5.11% dividend yield and 5% upside to consensus price target of $82.18, though revenue declines and competitive pressures in consumer electronics remain key risks. Analyst sentiment is mixed with 34% buy ratings versus 53% hold, reflecting cautious optimism about the turnaround strategy under new CEO Jason Bonfig.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →
